JP2022553083A5 - - Google Patents

Info

Publication number
JP2022553083A5
JP2022553083A5 JP2022523915A JP2022523915A JP2022553083A5 JP 2022553083 A5 JP2022553083 A5 JP 2022553083A5 JP 2022523915 A JP2022523915 A JP 2022523915A JP 2022523915 A JP2022523915 A JP 2022523915A JP 2022553083 A5 JP2022553083 A5 JP 2022553083A5
Authority
JP
Japan
Prior art keywords
raav
composition
sequence
vector
inh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553083A (ja
JP7659550B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056984 external-priority patent/WO2021081280A1/en
Publication of JP2022553083A publication Critical patent/JP2022553083A/ja
Publication of JP2022553083A5 publication Critical patent/JP2022553083A5/ja
Priority to JP2025055764A priority Critical patent/JP2025098221A/ja
Application granted granted Critical
Publication of JP7659550B2 publication Critical patent/JP7659550B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523915A 2019-10-23 2020-10-23 アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療 Active JP7659550B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025055764A JP2025098221A (ja) 2019-10-23 2025-03-28 アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924877P 2019-10-23 2019-10-23
US62/924,877 2019-10-23
PCT/US2020/056984 WO2021081280A1 (en) 2019-10-23 2020-10-23 Adeno-associated virus vectors based gene therapy for hereditary angioedema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025055764A Division JP2025098221A (ja) 2019-10-23 2025-03-28 アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2022553083A JP2022553083A (ja) 2022-12-21
JP2022553083A5 true JP2022553083A5 (cg-RX-API-DMAC7.html) 2023-10-30
JP7659550B2 JP7659550B2 (ja) 2025-04-09

Family

ID=73498274

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523915A Active JP7659550B2 (ja) 2019-10-23 2020-10-23 アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療
JP2025055764A Ceased JP2025098221A (ja) 2019-10-23 2025-03-28 アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025055764A Ceased JP2025098221A (ja) 2019-10-23 2025-03-28 アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療

Country Status (5)

Country Link
US (1) US20230043051A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048800A1 (cg-RX-API-DMAC7.html)
JP (2) JP7659550B2 (cg-RX-API-DMAC7.html)
CN (1) CN115176022A (cg-RX-API-DMAC7.html)
WO (1) WO2021081280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230340078A1 (en) * 2019-11-14 2023-10-26 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with liver-specific gene therapy vectors
EP4263614A1 (en) * 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
KR20230136147A (ko) * 2021-01-27 2023-09-26 스파크 테라퓨틱스, 인코포레이티드 유전성 혈관부종을 치료하기 위한 조성물 및 방법
TW202332472A (zh) * 2021-10-01 2023-08-16 美商拜奧馬林製藥公司 利用aav基因療法載體進行之遺傳性血管水腫治療及治療性調配物
CN117947040A (zh) 2022-10-31 2024-04-30 苏州荷光科汇生物科技有限公司 用于目的基因的表达盒及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
EP1737966B1 (en) 2004-04-02 2012-05-09 Board of Regents, The University of Texas System Cancer specific promoters
US9617548B2 (en) 2008-04-22 2017-04-11 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
GB201206455D0 (en) 2012-04-12 2012-05-30 Royal Holloway & Bedford New College Gene expression
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
WO2014063753A1 (en) 2012-10-26 2014-05-01 Vrije Universiteit Brussel Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof
AU2014228765A1 (en) 2013-03-15 2015-10-15 Medimmune, Llc Palivizumab epitope-based virus-like particles
JP6754361B2 (ja) 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
CL2014003590A1 (es) 2014-12-30 2015-07-10 Univ Chile Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
JP6879486B2 (ja) * 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel Fviiiおよびfix用の最適化された肝臓特異的発現系
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
KR20180014051A (ko) * 2015-05-28 2018-02-07 코넬 유니버시티 혈관 부종 치료제로서의 아데노-관련 바이러스 매개 c1e1의 전달
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
US10190135B2 (en) 2015-10-27 2019-01-29 Celltheon Corporation Chimeric post-transcriptional regulatory element
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
WO2017139381A1 (en) * 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
AU2017248259A1 (en) 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
CN109844124B (zh) 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
ES3024357T3 (en) 2017-02-17 2025-06-04 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
EP3740581A4 (en) * 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY

Similar Documents

Publication Publication Date Title
JP2022524434A5 (cg-RX-API-DMAC7.html)
JP2021087431A5 (cg-RX-API-DMAC7.html)
JP2019513393A5 (cg-RX-API-DMAC7.html)
AU2018304194B2 (en) Apheresis methods and uses
JP2020513811A5 (cg-RX-API-DMAC7.html)
JP2023520402A5 (cg-RX-API-DMAC7.html)
JP2025515979A5 (cg-RX-API-DMAC7.html)
JP2020510447A5 (cg-RX-API-DMAC7.html)
JP2021512072A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2021513999A5 (cg-RX-API-DMAC7.html)
FI3906066T3 (fi) Geeniterapiakonstrukteja wilsonin taudin hoitamiseksi
JP2016512683A5 (cg-RX-API-DMAC7.html)
JP2017512466A5 (cg-RX-API-DMAC7.html)
RU2015144234A (ru) Композиции и способы лечения mps1
JP2022536692A5 (cg-RX-API-DMAC7.html)
RU2019133002A (ru) ЭКСПРЕССИОННЫЕ КАССЕТЫ MeCP2
JP2020054367A (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2023520764A5 (cg-RX-API-DMAC7.html)
JP2023537904A5 (cg-RX-API-DMAC7.html)
IL262852B1 (en) Treatment of complement-mediated disorders
JP2023517934A5 (cg-RX-API-DMAC7.html)
JP2022513318A5 (cg-RX-API-DMAC7.html)
FI3953377T3 (fi) Geeniterapioita lysosomaalisiin sairauksiin